ICML 2023 | Investigating the prognostic impact of immunoarchitectural patterns in NLPHL
Michael Binkley, MD, MS, Stanford University School of Medicine, Stanford, CA, shares some insights into a study conducted by the Global NLPHL One Working Group (GLOW) which investigated the prognostic significance of immunoarchitectural patterns in pediatric and adult patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), and highlights the development of a novel prognostic score for these patients. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So nodular lymphocyte predominant Hodgkin lymphoma is a rare subtype of Hodgkin lymphoma. Prior studies have focused on investigating outcomes for patients in adult age range or pediatric age range, and there’s been a lack of data when looking across ages and including all clinical stages. So that was the motivation behind the Global NLPHL One Working Group or GLOW performing this study that included patients of all ages and clinical stages...
So nodular lymphocyte predominant Hodgkin lymphoma is a rare subtype of Hodgkin lymphoma. Prior studies have focused on investigating outcomes for patients in adult age range or pediatric age range, and there’s been a lack of data when looking across ages and including all clinical stages. So that was the motivation behind the Global NLPHL One Working Group or GLOW performing this study that included patients of all ages and clinical stages. Additionally, there has been some controversy about the prognostic significance of immunoarchitectural patterns for NLPHL, and there has been a lack of data in looking at outcomes for individual variant patterns. And so GLOW was able to perform this comprehensive study looking at a large cohort of patients of all ages and all clinical stages with a large percentage, almost half having pathology scored. And with this large cohort we were able to develop a lymphocyte predominant international prognostic score that is able to risk stratify patients into low-risk and high-risk, with the goal of informing prospective clinical trials, studying deintensification of therapy for those that are at low risk of either progression, lymphoma-specific death or transformation.
Read more...
